AU2002257587B2 - Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors - Google Patents

Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors Download PDF

Info

Publication number
AU2002257587B2
AU2002257587B2 AU2002257587A AU2002257587A AU2002257587B2 AU 2002257587 B2 AU2002257587 B2 AU 2002257587B2 AU 2002257587 A AU2002257587 A AU 2002257587A AU 2002257587 A AU2002257587 A AU 2002257587A AU 2002257587 B2 AU2002257587 B2 AU 2002257587B2
Authority
AU
Australia
Prior art keywords
acid
pct
contain
inhalable
propellant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002257587A
Other languages
English (en)
Other versions
AU2002257587A1 (en
Inventor
Christopher John Montague Meade
Michel Pairet
Michael Paul Pieper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of AU2002257587A1 publication Critical patent/AU2002257587A1/en
Application granted granted Critical
Publication of AU2002257587B2 publication Critical patent/AU2002257587B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002257587A 2001-03-07 2002-02-26 Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors Ceased AU2002257587B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10110772.2 2001-03-07
DE10110772A DE10110772A1 (de) 2001-03-07 2001-03-07 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
PCT/EP2002/001988 WO2002069945A2 (de) 2001-03-07 2002-02-26 Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren

Publications (2)

Publication Number Publication Date
AU2002257587A1 AU2002257587A1 (en) 2003-03-13
AU2002257587B2 true AU2002257587B2 (en) 2007-05-10

Family

ID=7676493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002257587A Ceased AU2002257587B2 (en) 2001-03-07 2002-02-26 Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors

Country Status (18)

Country Link
EP (1) EP1372649B1 (enrdf_load_stackoverflow)
JP (1) JP2004521134A (enrdf_load_stackoverflow)
KR (1) KR20030081501A (enrdf_load_stackoverflow)
CN (1) CN1649588A (enrdf_load_stackoverflow)
AR (1) AR034213A1 (enrdf_load_stackoverflow)
AU (1) AU2002257587B2 (enrdf_load_stackoverflow)
BR (1) BR0207883A (enrdf_load_stackoverflow)
CA (1) CA2439763C (enrdf_load_stackoverflow)
CZ (1) CZ20032635A3 (enrdf_load_stackoverflow)
DE (1) DE10110772A1 (enrdf_load_stackoverflow)
EA (1) EA009989B1 (enrdf_load_stackoverflow)
HU (1) HUP0400782A3 (enrdf_load_stackoverflow)
IL (2) IL157326A0 (enrdf_load_stackoverflow)
MX (1) MXPA03008045A (enrdf_load_stackoverflow)
NZ (1) NZ528621A (enrdf_load_stackoverflow)
PL (1) PL363078A1 (enrdf_load_stackoverflow)
TW (1) TWI332833B (enrdf_load_stackoverflow)
WO (1) WO2002069945A2 (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005210084B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
US8513279B2 (en) 1999-07-14 2013-08-20 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216588T2 (de) * 2001-05-25 2007-09-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
DK1610787T3 (da) * 2003-03-28 2008-06-02 Nycomed Gmbh Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
MXPA05010161A (es) * 2003-03-28 2005-11-16 Altana Pharma Ag Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
JP2007500148A (ja) * 2003-07-28 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅｉｖ阻害薬と新規な抗コリン作用薬とを含有する医薬品ならびに呼吸器疾患治療のための該医薬品の使用
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
EP1504756A1 (en) * 2003-08-06 2005-02-09 Kyowa Hakko Kogyo Co., Ltd Medicament compositions comprising a heterocyclic compound and an anticholinergic
EP1706118A1 (en) * 2004-01-09 2006-10-04 Boehringer Ingelheim International GmbH New pharmaceutical compositions based on a scopineester and nicotinamide derivatives
PL1713473T3 (pl) 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
CN1913882A (zh) * 2004-02-06 2007-02-14 Meda制药有限及两合公司 用抗胆碱能药单独或联合抗组胺药、磷酸二酯酶4抑制剂或皮质类固醇来治疗鼻炎
JP2007524699A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラストとグリコピロニウムとの組合せ物
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
RU2420285C2 (ru) 2005-03-16 2011-06-10 Меда Фарма Гмбх Унд Ко.Кг Комбинация r,r-гликопирролата и монтелукаста для лечения респираторных заболеваний и фармацевтическая композиция на ее основе
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
SI2098248T1 (sl) 2005-12-21 2012-09-28 Meda Pharma Gmbh & Co Kg Kombinacija antiholinergikov, glukokortikoidov in beta-2-agonistov za zdravljenje vnetnih bolezni
PT2046787E (pt) 2006-08-01 2011-06-15 Glaxo Group Ltd Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
MX2011007499A (es) 2009-01-13 2011-08-04 Glaxo Group Ltd Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102670607A (zh) * 2012-05-28 2012-09-19 海南卫康制药(潜山)有限公司 复方盐酸氨溴索组合物及其制备方法
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
BR112015029749A2 (pt) * 2013-05-31 2017-07-25 Incipio Devices Sa conjunto do escareador acetabular

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040829A2 (en) * 1998-12-30 2000-10-04 Pfizer Inc. Prokinetic agents for treating gastric hypomotility and related disorders
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
WO2001057025A1 (en) * 2000-01-31 2001-08-09 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
WO2001070746A1 (fr) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derives de furoisoquinoleine, leur procede de production et leur utilisation
WO2001078741A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and budesonide
WO2002009689A1 (en) * 2000-07-27 2002-02-07 Smithkline Beecham Corporation Method for reducing exacerbations associated with copd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040829A2 (en) * 1998-12-30 2000-10-04 Pfizer Inc. Prokinetic agents for treating gastric hypomotility and related disorders
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
WO2001057025A1 (en) * 2000-01-31 2001-08-09 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
WO2001070746A1 (fr) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derives de furoisoquinoleine, leur procede de production et leur utilisation
WO2001078741A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and budesonide
WO2002009689A1 (en) * 2000-07-27 2002-02-07 Smithkline Beecham Corporation Method for reducing exacerbations associated with copd

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513279B2 (en) 1999-07-14 2013-08-20 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US8802699B2 (en) 1999-07-14 2014-08-12 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
AU2005210084B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation

Also Published As

Publication number Publication date
KR20030081501A (ko) 2003-10-17
CZ20032635A3 (cs) 2004-09-15
CA2439763C (en) 2012-10-16
JP2004521134A (ja) 2004-07-15
EA009989B1 (ru) 2008-04-28
IL157326A0 (en) 2004-02-19
HUP0400782A3 (en) 2012-09-28
WO2002069945A2 (de) 2002-09-12
MXPA03008045A (es) 2003-12-04
WO2002069945A3 (de) 2003-01-30
TWI332833B (en) 2010-11-11
CA2439763A1 (en) 2002-09-12
CN1649588A (zh) 2005-08-03
DE10110772A1 (de) 2002-09-12
IL157326A (en) 2011-12-29
EP1372649A2 (de) 2004-01-02
AR034213A1 (es) 2004-02-04
PL363078A1 (en) 2004-11-15
HUP0400782A2 (hu) 2004-07-28
NZ528621A (en) 2005-04-29
EA200300929A1 (ru) 2004-04-29
BR0207883A (pt) 2004-07-27
EP1372649B1 (de) 2012-07-25

Similar Documents

Publication Publication Date Title
AU2002257587B2 (en) Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors
US20020193393A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CA2431565C (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
US20040058950A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US7417051B2 (en) Medicaments comprising betamimetics and a novel anticholinergic
CA2733294C (en) Pharmaceutical combination of a tiotropium salt and ciclesonide
AU2002227910B2 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
US20070208060A1 (en) Compounds for treating inflammatory diseases
US20040176338A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
AU2003232201B2 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
US20020151541A1 (en) Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
WO2004024156A1 (en) Tiotropium salts for reducing respiratory mortality rate
US20020122773A1 (en) Pharmaceutical compositions based on anticholinergics and dopamine agonists
AU2003216921B2 (en) Medicaments containing steroids and a novel anticholinesterase drug
US20030203918A1 (en) Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound
US20020193394A1 (en) Compounds for treating inflammatory diseases
CA2492026A1 (en) New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors
NZ535166A (en) New medicinal compositions on the basis of anticholinergic agents and EGFR kinase inhibitors
CA2441964C (en) New pharmaceutical compositions based on anticholinergics and endothelin antagonists
CA2436537C (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines
ZA200306221B (en) Novel medicament compositions on the basis of anti-cholinergics and PDE IV inhibitors.
CA2635649A1 (en) New pharmaceutical compositions based on anticholinergics and andolast
CA2430592C (en) New pharmaceutical compositions based on anticholinergics and dopamine agonists
CA2614631C (en) Pharmaceutical compositions based on anticholinergics and corticosteroids in the form of an inhalable solution or suspension

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired